Key facts
- Sparrow Pharmaceuticals’s last known valuation is $139.0M (Sep 2025).
- It has raised $145.8M across 4 recorded rounds; the latest was Later Stage VC (Series B) ($95.0M) in Sep 2025.
- Notable investors include RA Capital Management, Keiretsu Forum, Matter (Consulting Services (B2B)), OrbiMed, Forbion — 11 tracked in total.
- Sparrow Pharmaceuticals has filed 5 Form Ds with the SEC since 2019, most recently Jul 2025 ($61.8M sold to 17 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Sparrow Pharmaceuticals
Funding rounds
4 roundsAbout Sparrow Pharmaceuticals
Operator of a cardiometabolic therapeutics platform intended to address treatment-resistant diabetes and related metabolic conditions. The company offers a novel oral hydroxysteroid dehydrogenase type 1 inhibitor targeting disease progression mechanisms, enabling patients with type 2 diabetes and elevated cortisol to achieve improved glycemic control with fewer side effects and simplified treatment.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Portland, OR, United States
- Founded
- 2013
- Employees
- 10
- Website
- sparrowpharma.com/
- Ownership
- Privately Held (backing)
Sparrow Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sparrow Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sparrow Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.